Farms.com Home   News

US seeks new markets for meat exports

US meat industry looks to diversify markets amid China slowdown

By Farms.com

The US meat industry is setting its sights on Central Asia as a new market for its products. This shift comes as China, a major US meat importer, has been buying significantly less beef and poultry this year.

To tap into Central Asian markets, the US recently secured agreements with Uzbekistan and Kazakhstan. Uzbekistan agreed to allow US meat imports, while Kazakhstan will certify more US meat production facilities. These deals follow a meeting between US trade officials and Central Asian nations.

The decline in Chinese demand is attributed to factors like increased competition and trade tensions. The US has found success in other markets. For instance, US beef exports to Mexico have reached a 10-month high. Similarly, the poultry industry has seen growth in countries like Vietnam and the Philippines.

Despite these bright spots, the US poultry sector is still struggling to fully replace the lost Chinese market. This underscores the ongoing challenge for US agriculture in diversifying its meat export destinations.


Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.